Study of Anlotinib-based Combination Therapy for Women with Hormone Receptor-positive Metastatic Breast Cancer After CDK46 Inhibitor Resistance

What this Trial Is About

Researchers are evaluating the safety and effectiveness of anlotinib-based combination therapy in female patients with hormone receptor-positive HR, HER2-negative metastatic breast cancer MBC who have already been treated with CDK46 inhibitors. This study focuses on patients whose cancer has progressed after receiving standard treatments including CDK46 inhibitors combined with hormonal therapy, aiming to find new options for this resistant stage of disease. The study involves administering anlotinib, an oral multi-target tyrosine kinase inhibitor given daily for 14 days in each cycle, with doses adjusted based on tolerance. Anlotinib is combined with other agents such as eribulin, nab-paclitaxel, etoposide, capecitabine, pembrolizumab, sintilimab, or fulvestrant. This real-world study observes patients over an average of one year to assess treatment response and safety. Participants will be monitored through assessments of progression-free survival, objective response rate, disease control rate, overall survival up to five years, and treatment-emergent adverse events. The study includes regular evaluations of measurable lesions and overall health status. Women between 18 and 75 years old with confirmed HR HER2-negative breast cancer and prior CDK46 inhibitor treatment are eligible, with safety and effectiveness tracked throughout the study period.

Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .